ViroPharma Inc. (VPHM) announced Tuesday morning that the FDA denied the citizen petition filed by ViroPharma on March 17, 2006, related to the FDA's proposed in vitro method for determining bioequivalence of abbreviated new drug applications referencing Vancocin Capsules. The FDA also approved three generic versions of the drug.
ViroPharma gapped open dramatically lower Tuesday, but was range-bound throughout the session. The stock finished down by 6.17 at $22.44 on the highest volume of the year. ViroPharma sank to over a 4-month low and fell below its 200-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.